Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Siskind

Showing results (251-260 of 292) with videos related to

Pageof 30
Sort By:
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 10, 2019
The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trialsJoseph Firth, Scott B Teasdale, Kelly Allott, et al.
The Australian and New Zealand Journal of Psychiatry|December 13, 2019
Meta-analysis of randomised controlled trials with <i>N</i>-acetylcysteine in the treatment of schizophreniaCaitlin Ob Yolland, Donal Hanratty, Erica Neill, et al.
Diabetes, Obesity & Metabolism|September 7, 2018
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysisDan Siskind, Margaret Hahn, Christoph U Correll, et al.
BMC Psychiatry|September 16, 2016
N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptomsSusan L Rossell, Paul S Francis, Cherrie Galletly, et al.
Molecular Psychiatry|October 11, 2023
Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trialsMichele Fornaro, Claudio Caiazza, Niccolò Solini, et al.
Nutritional Neuroscience|May 31, 2018
Improvement of cognitive function in schizophrenia with <i>N</i>-acetylcysteine: A theoretical reviewCaitlin O B Yolland, Andrea Phillipou, David J Castle, et al.
Schizophrenia Bulletin|July 20, 2022
N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative SymptomsErica Neill, Susan L Rossell, Caitlin Yolland, et al.
The Australian and New Zealand Journal of Psychiatry|May 26, 2025
New hope for individuals with schizophrenia: A transdisciplinary research platform to discover and translate novel treatmentsJames McLure, Urska Arnautovska, Bruna Panizzutti, et al.
The Lancet. Psychiatry|July 5, 2025
Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panelDan Siskind, Korinne Northwood, Toby Pillinger, et al.
Brain, Behavior, & Immunity - Health|June 18, 2025
Relationship between blood-cerebrospinal fluid barrier integrity, cardiometabolic, and inflammatory factors in schizophrenia-spectrum disordersVladislav Yakimov, Iris Jäger, Lukas Roell, et al.
Pageof 30

Showing results (251-260 of 292) with videos related to

Sort By:
Pageof 30
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|September 10, 2019
The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trialsJoseph Firth, Scott B Teasdale, Kelly Allott, et al.
The Australian and New Zealand Journal of Psychiatry|December 13, 2019
Meta-analysis of randomised controlled trials with <i>N</i>-acetylcysteine in the treatment of schizophreniaCaitlin Ob Yolland, Donal Hanratty, Erica Neill, et al.
Diabetes, Obesity & Metabolism|September 7, 2018
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysisDan Siskind, Margaret Hahn, Christoph U Correll, et al.
BMC Psychiatry|September 16, 2016
N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptomsSusan L Rossell, Paul S Francis, Cherrie Galletly, et al.
Molecular Psychiatry|October 11, 2023
Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trialsMichele Fornaro, Claudio Caiazza, Niccolò Solini, et al.
Nutritional Neuroscience|May 31, 2018
Improvement of cognitive function in schizophrenia with <i>N</i>-acetylcysteine: A theoretical reviewCaitlin O B Yolland, Andrea Phillipou, David J Castle, et al.
Schizophrenia Bulletin|July 20, 2022
N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative SymptomsErica Neill, Susan L Rossell, Caitlin Yolland, et al.
The Australian and New Zealand Journal of Psychiatry|May 26, 2025
New hope for individuals with schizophrenia: A transdisciplinary research platform to discover and translate novel treatmentsJames McLure, Urska Arnautovska, Bruna Panizzutti, et al.
The Lancet. Psychiatry|July 5, 2025
Absolute neutrophil count and adverse drug reaction monitoring during clozapine treatment: consensus guidelines from a global Delphi panelDan Siskind, Korinne Northwood, Toby Pillinger, et al.
Brain, Behavior, & Immunity - Health|June 18, 2025
Relationship between blood-cerebrospinal fluid barrier integrity, cardiometabolic, and inflammatory factors in schizophrenia-spectrum disordersVladislav Yakimov, Iris Jäger, Lukas Roell, et al.
Pageof 30